Sidley represented Shanghai MicroPort MedBot (Group) Co., Ltd. (HKEX: 2252) (MicroPort MedBot) in connection with its placing of 34.7 million new H shares under general mandate. The net proceeds to be received from the placing are estimated to be approximately HK$266.31 million (US$34.2 million). The placing agents are J.P. Morgan Securities (Asia Pacific) Limited and China International Capital Corporation Hong Kong Securities Limited.
MicroPort MedBot is the first HKEX-listed, globally top-tier surgical robot company, dedicated to designing, developing, and commercializing surgical robots to assist surgeons in performing complex surgical procedures.
The Sidley team was led by partner Sherlyn Lau, other team members included senior managing associate Alex Chau and associate Bailey Wei.
In November 2021, Sidley represented MicroPort MedBot in its initial public offering (IPO) and H share listing on the Main Board of The Stock Exchange of Hong Kong under Chapter 18A of the Hong Kong Listing Rules. We also advised on its placing of 12.9 million new H shares under general mandate in June 2024.
